Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines

Hasumati Rahalkar, Hacer Coskun Cetintas, Mir-Saeed Shayegan Salek

Research output: Contribution to journalReview articlepeer-review

137 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines'. Together they form a unique fingerprint.

Medicine & Life Sciences